AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33407910
Drug: iACT (app-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iACT (app-assisted acceptance and commitment therapy)
Trial: 33407947
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention (12-weekly sessions on education, physical activity, stress management, coping skills training) followed by 3 months of continued support and 6 months of skill maintenance
Trial: 33408796
Drug: Sustained Acoustic
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Acoustic Medicine (SAM) combined with 1% diclofenac ultrasound gel patch
Trial: 33409867
Drug: Subcutaneous IgPro20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20 at 25 mL, Volume Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20 at 40 mL, Volume Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20 at 25 mL/h, Flow Rate Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20 at 75 mL/h, Flow Rate Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20 at 100 mL/h, Flow Rate Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20, Volume Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20, Flow Rate Cohort
Trial: 33409867
Drug: Subcutaneous IgPro20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IgPro20
Trial: 33409898
Drug: Vorinostat 200
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 200 mg orally twice daily continuously until progression or unacceptable toxicity
Trial: 33410093
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30/70 (BIAsp 30) in an insulin pen (FlexPen)
Trial: 33410109
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) and Indapamide combination
Trial: 33410485
Drug: Intra-articular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid injection
Trial: 33410523
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag (EPAG) plus standard immunosuppressive therapy (IST)
Trial: 33410959
Drug: GTV1 before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTV1 before RCT (mean 154.4 ml, 95% CI: 1.5-877)
Trial: 33410959
Drug: GTV2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTV2 at 40-50 Gy (mean 106.2 ml, 95% CI: 0.5-589.5)
Trial: 33411824
Drug: ADRe-p intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADRe-p intervention (Adverse Drug Reaction Profile for polypharmacy)
Trial: 33411897
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg subcutaneously at least 1 week before the first cycle of chemotherapy and then every 4 weeks during chemotherapy)
Trial: 33413366
Drug: Insulin Sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Sensitive (IS)
Trial: 33413552
Drug: Before treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before treatment (BT) group
Trial: 33413583
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion for 6 hours to decrease heart rate by 20%.
Trial: 33413583
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion for 6 hours.
Trial: 33414259
Drug: Pharmaceutical interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical interventions (PIs) by clinical pharmacist during the PICC process
Trial: 33414758
Drug: Repository Corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository Corticotropin Injection (Acthar® Gel)
Trial: 33414828
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg/d) tapered off by week 24
Trial: 33415416
Drug: Quizartinib dihydrochloride
RxNorm normalized name: QUIZARTINIB DIHYDROCHLORIDE
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib dihydrochloride (20, 30, and 60 mg daily)
Trial: 33415656
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement device (MAD) therapy for 1 month
Trial: 33415656
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement device (MAD) therapy for 6 months
Trial: 33416257
Drug: Mobilization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization therapy (level + duration)
Trial: 33416257
Drug: Mobilization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization therapy (duration)
Trial: 33416257
Drug: Mobilization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization therapy (level)
Trial: 33416500
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (10 sessions over 2 weeks and 20 sessions over 4 weeks)
Trial: 33416995
Drug: Oral Symptom
RxNorm normalized name: Pamprin Multi-Symptom Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Symptom Assessment Scale (OSAS)
Trial: 33417474
Drug: Risk-adapted preemptive
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-adapted preemptive tocilizumab (8-12 mg/kg)
Trial: 33417511
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg once every 3 weeks) plus Ipilimumab (3 mg/kg once every 3 weeks) for four inductions, followed by Nivolumab (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.
Trial: 33417814
Drug: Antidepressant treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment, details not available
Trial: 33418143
Drug: Speech Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech Therapy App (STAPP)
Trial: 33420229
Drug: Everolimus daily
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus daily orally at 10 mg for 12 weeks
Trial: 33420642
Drug: Fluzoparib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib (100 mg, p.o.) after meal consumption on day-1
Trial: 33420642
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg (p.o.) under fasting condition from day-5 to day-9
Trial: 33420642
Drug: Fluzoparib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib (100 mg, p.o.) after meal consumption on day-9
Trial: 33420682
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of antithrombotic drugs used (0 to 8, interquartile range = 3-4)
Trial: 33421178
Drug: Panobinostat 30
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat 30 mg and Carfilzomib 20/56 mg/m²
Trial: 33422025
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment strategies for tibial shaft fractures (TSFs) including various surgical techniques and implant materials, with no specific dosage or duration mentioned.
Trial: 33422025
Drug: Systemic perioperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic perioperative antibiotic prophylaxis, local antimicrobials, and timing of soft-tissue coverage.
Trial: 33422139
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) at a single dose of 1 × 10
Trial: 33422139
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs)
Trial: 33425441
Drug: Preoperative intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX) for 3, 21-day courses
Trial: 33425441
Drug: Preoperative intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX)
Trial: 33425673
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of zoledronate
Trial: 33425673
Drug: 6-monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-monthly dosing of zoledronate
Trial: 33425801
Drug: Tamsulosin HCl
RxNorm normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin HCl 0.2 mg in the fed state with a high-fat meal
Trial: 33425801
Drug: Tamsulosin HCl
RxNorm normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin HCl 0.4 mg in the fed state with a high-fat meal
Trial: 33425801
Drug: Tamsulosin HCl
RxNorm normalized name: tamsulosin HCl
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin HCl 0.4 mg in the fasted state
Trial: 33427211
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors with high matching score (≥50%)
Trial: 33427211
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors with low matching score (<50%)
Trial: 33427211
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors (high matching score)
Trial: 33427211
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors (low matching score)
Trial: 33427685
Drug: Metformin-containing medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-containing medication
Trial: 33430634
Drug: Extended window
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended window endovascular stroke therapy
Trial: 33430807
Drug: PTSD scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTSD scale administered at five-month follow-up
Trial: 33430930
Drug: Sedative agents
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative agents (propofol and fentanyl)
Trial: 33431018
Drug: Shared Decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared Decision Making (SDM) Antipsychotic Medication Decision Aid
Trial: 33432540
Drug: Biosimilar etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biosimilar etanercept 25 mg twice weekly or 50 mg once weekly
Trial: 33432547
Drug: SAR341402 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR341402 insulin aspart (SAR-Asp)
Trial: 33432547
Drug: NN-Asp (NovoLog®/NovoRapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN-Asp (NovoLog®/NovoRapid® insulin aspart)
Trial: 33433145
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (42 patients)
Trial: 33433355
Drug: TGF-β1 (pro-fibrotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-β1 (pro-fibrotic agent)
Trial: 33433743
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies involving immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1)
Trial: 33433743
Drug: Future approaches
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [FUTURE TIME]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Future approaches involving bispecific antibodies and CAR-T cells
Trial: 33434161
Drug: rhIGF1 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF1 therapy
Trial: 33434221
Drug: Corticosteroid immunomodulatory
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid immunomodulatory therapy
Trial: 33434221
Drug: IP-10 levels
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP-10 levels exceeding 1,000 pg/mL
Trial: 33434290
Drug: Long-term bisphosphonate
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term bisphosphonate therapy in patients with atypical femur fracture (AFF)
Trial: 33434290
Drug: Long-term bisphosphonate
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term bisphosphonate therapy in patients without atypical femur fracture (non-AFF)
Trial: 33434314
Drug: 80 μg abaloparatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg abaloparatide daily
Trial: 33435973
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT
Trial: 33436023
Drug: Geptanolimab 3
RxNorm normalized name: Geptanolimab
DrugBank: Geptanolimab (DB16417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geptanolimab 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Trial: 33436455
Drug: Average annual
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average annual medication costs per patient
Trial: 33436455
Drug: Ratio of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratio of medication to total health care costs
Trial: 33436455
Drug: Medication classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication classes
Trial: 33436493
Drug: Alteplase 20
RxNorm normalized name: alteplase 20 mg INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 20 mg and 10 mg (combined)
Trial: 33436675
Drug: MTf-targeting antibody-drug
RxNorm normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTf-targeting antibody-drug conjugate (ADC)
Trial: 33436744
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg taken once daily for three months
Trial: 33437832
Drug: Twice-daily IVR
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily IVR call reminders with self-management support messaging, plus a weekly IVR adherence assessment
Trial: 33437832
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control with only weekly IVR adherence assessment
Trial: 33437832
Drug: Twice-daily IVR
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily IVR call reminders
Trial: 33438069
Drug: Bevacizumab (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5-15 mg/kg) administered every 2 or 3 weeks, with or without chemotherapy
Trial: 33438092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEP and MIP measurements.
Trial: 33439382
Drug: FLT3 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FLT3 inhibitors
Trial: 33439382
Drug: Advanced risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced risk stratification and new treatment strategies
Trial: 33439463
Drug: MenACWY-DT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-DT vaccine
Trial: 33439866
Drug: tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
Trial: 33439866
Drug: tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tumor necrosis factor receptor 1 (TNF-R1)
Trial: 33441162
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiation therapy (SABR)
Trial: 33441449
Drug: Women with
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with concurrent rectal CT
Trial: 33443137
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (coiling or BAC)
Trial: 33444199
Drug: Anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant treatment with rivaroxaban
Trial: 33445952
Drug: Mechanical deligation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical deligation with intravenous recombinant tissue plasminogen activator administered 2 days after deligation
Trial: 33445952
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator administered at day 4
Trial: 33446655
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine with saponin-based Matrix-M adjuvant
Trial: 33446895
Drug: Exposure and
RxNorm normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure and ritual prevention (EX/RP) therapy, 17 sessions, twice weekly
Trial: 33447520
Drug: Nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analogue therapy
Trial: 33448286
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy (MT) emphasizing parent-led infant-directed singing during NICU hospitalization and across 3 months post-discharge
Trial: 33448731
Drug: Daily Truvada
RxNorm normalized name: Truvada
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily Truvada (HIV preexposure prophylaxis)
Trial: 33448893
Drug: Ofatumumab maintenance
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab maintenance after induction therapy
Trial: 33449428
Drug: Targeted Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted Drug Delivery (TDD) for chronic nonmalignant pain
Trial: 33449813
Drug: Eprenetapopt (APR-246)
RxNorm normalized name: PrameGel Reformulated Apr 2012
DrugBank: Eprenetapopt (DB11684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprenetapopt (APR-246) in combination with azacitidine
Trial: 33450367
Drug: Endovascular treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatments in individuals with cerebral infarct
Trial: 33451297
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant (DEX implant)
Trial: 33451780
Drug: Sci-B-Vac® (tri-antigenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sci-B-Vac® (tri-antigenic recombinant Hepatitis B vaccine)
Trial: 33453294
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with hyperglycemia (≥140 mg/dl)
Trial: 33453294
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with normal glucose levels (<140 mg/dl)
Trial: 33454128
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol for phosphate repletion
Trial: 33454601
Drug: Immunosuppressant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant treatments
Trial: 33454817
Drug: Antibiotic-first therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-first therapy
Trial: 33455802
Drug: Ropivacaine 0.2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2%, 200 ml (400 mg) injected peri-articularly in each knee